Enteropathy-associated T-cell lymphoma

Last reviewed March 21, 2026

🖨 Print for my doctor Advocacy Hub →

ORPHA:86880C86.2

Who is this for?

Show terms as

19Specialists 8Treatment centers

Where are you in your journey?

ℹ

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.

Report missing data

Overview

Also known as:

EATL ETTL Enteropathy-type T-cell lymphoma Intestinal T-cell lymphoma Enteropathy-associated T-cell lymphoma type 1

Orphanet ↗NORD ↗

FDA & Trial Timeline

2 events

Feb 2026Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

City of Hope Medical Center — PHASE2

TrialRECRUITING

Dec 2024Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients

Ruijin Hospital — PHASE2

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Enteropathy-associated T-cell lymphoma.

View clinical trials →

Clinical Trials

View all trials with filters →

No actively recruiting trials found for Enteropathy-associated T-cell lymphoma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Enteropathy-associated T-cell lymphoma community →

Specialists

19 foundView all specialists →

AH

Alex F Herrera

Specialist

ALK-negative anaplastic large cell lymphoma ALK-positive anaplastic large cell lymphoma Classic Hodgkin lymphoma+10 more

PI on 7 active trials

Active trials Directions Travel grants

PM

Paolo Caimi, MD

CLEVELAND, OH

Specialist

Acute erythroid leukemia Acute lymphoblastic leukemia ADULT syndrome+28 more

PI on 5 active trials

Active trials Directions Travel grants

SM

Steven Horwitz, MD

Specialist

Adult T-cell leukemia/lymphoma Aggressive NK-cell leukemia Aggressive primary cutaneous T-cell lymphoma+22 more

PI on 4 active trials

Active trials Directions Travel grants

DM

Deepa Jagadeesh, MD, MPH

WORCESTER, MA

Specialist

B-cell non-Hodgkin lymphoma Post-transplant lymphoproliferative disease

PI on 4 active trials

Active trials Directions Travel grants

TM

Thomas E. Witzig, MD

ROCHESTER, MN

Specialist

Acute lymphoblastic leukemia Aggressive B-cell non-Hodgkin lymphoma Aggressive NK-cell leukemia+21 more

PI on 9 active trials

Active trials Directions Travel grants

ML

Matthew A Lunning

OMAHA, NE

Specialist

ALK-negative anaplastic large cell lymphoma ALK-positive anaplastic large cell lymphoma Angioimmunoblastic T-cell lymphoma+1 more

PI on 1 active trial

Active trials Directions Travel grants

GM

Geoffrey Uy, M.D.

SAINT LOUIS, MO

Specialist

Monomorphic epitheliotropic intestinal T-cell lymphoma Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement NK-cell enteropathy

PI on 2 active trials

Active trials Directions Travel grants

YM

Yeow Tee Goh, MBBS MMed

Specialist

Hepatosplenic T-cell lymphoma NK-cell enteropathy

PI on 1 active trial

Active trials Directions Travel grants

MM

Max J Gordon, M.D.

Specialist

Monomorphic epitheliotropic intestinal T-cell lymphoma

PI on 1 active trial

Active trials Directions Travel grants

WM

Wan-Jen Hong, MD

STANFORD, CA

Specialist

Aggressive NK-cell leukemia Aggressive primary cutaneous T-cell lymphoma Hepatosplenic T-cell lymphoma+7 more

PI on 1 active trial

Active trials Directions Travel grants

YM

Yasuhiro Oki, MD

HOUSTON, TX

Specialist

Classic hairy cell leukemia Classic Hodgkin lymphoma Non-Hodgkin lymphoma+1 more

PI on 4 active trials

Active trials Directions Travel grants

MF

Michelle Fanale

HOUSTON, TX

Specialist

Classic Hodgkin lymphoma

PI on 2 active trials

Active trials Directions Travel grants

JM

James N Kochenderfer, M.D.

BETHESDA, MD

Specialist

B-cell chronic lymphocytic leukemia Myelodysplastic/myeloproliferative disease Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement+2 more

PI on 6 active trials

Active trials Directions Travel grants

RP

Roger Strair, MD, PhD

CAMDEN, NJ

Specialist

Acquired cystic disease-associated renal cell carcinoma Acute erythroid leukemia Acute mast cell leukemia+14 more

PI on 10 active trials

Active trials Directions Travel grants

TW

Thomas Witzig

ROCHESTER, MN

Specialist

Blastic plasmacytoid dendritic cell neoplasm Diffuse large B-cell lymphoma of the central nervous system Interdigitating dendritic cell sarcoma+6 more

PI on 5 active trials

Active trials Directions Travel grants

HO

Hermine Olivier

Specialist

PI on 1 active trial

Active trials Directions Travel grants

SM

Samuel Y Ng, M.D.

Specialist

PI on 1 active trial

Active trials Directions Travel grants

NL

Noelle LoConte

MADISON, WI

Specialist

NK-cell enteropathy Undifferentiated connective tissue syndrome

PI on 1 active trial

Active trials Directions Travel grants

LP

Luca Marciani, PhD

Specialist

PI on 1 active trial

Active trials Directions Travel grants

Treatment Centers

8 centers

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Enteropathy-associated T-cell lymphoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Enteropathy-associated T-cell lymphomaForum →

No community posts yet. Be the first to share your experience with Enteropathy-associated T-cell lymphoma.

Start the conversation →

Latest news about Enteropathy-associated T-cell lymphoma

1 articles

Clinical trialUNITERAREApr 3, 2026

New Recruiting Trial: Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

Researchers are testing a new type of cell therapy made from umbilical cord blood to treat T-cell lymphoma that has stopped responding to other treatments. The …

See all news about Enteropathy-associated T-cell lymphoma →

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Enteropathy-associated T-cell lymphoma

Which specialists treat Enteropathy-associated T-cell lymphoma?

19 specialists and care centers treating Enteropathy-associated T-cell lymphoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.